Editorial: Le Monde

• Pharmaceutical giant Sanofi announced its intent to surrender 50% control of Opella, its over-the-counter product subsidiary, including Doliprane, to American investment fund, CD&R.
• Socialist parliamentarians have demanded the government oppose this move, arguing it threatens French health sovereignty.
• Sanofi justifies the move by saying it aims to focus on innovation and position itself as a leader in immunology.
• President Emmanuel Macron had vowed to strengthen France's health sovereignty in the wake of the pandemic.
• The government can impose an agreement between the State, Sanofi, and the buyer to preserve French production and jobs, but without a long-term guarantee.

Conclusion: The ongoing crisis highlights the devastating gap between political promises and their implementation, underlining sovereignty limitations in a globalized world.

---